- Country: United States
STAT+: Lilly bypasses Australian pharmacies with DTC model
Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
Latest coverage
- Country: United States
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
- Country: United States
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
The U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providers
- Country: United States
STAT+: NIH awarded all its grant funding, but delayed and opaque decisions stymied researchers
The NIH continued reducing grants involving health disparities, race, and ethnicity but made little progress toward other administration priorities in the 2026 fiscal year.
- Country: United States
STAT+: Medicare Advantage plans shift more costs onto seniors in 2027
Premiums are stable, but Medicare Advantage plans are making big changes that could make care more expensive for patients.
- Country: United States
STAT+: A journey to witness China’s biotech boom up close
Chinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making American's nervous.
- Country: United States
STAT+: MAHA goes corporate
Health care companies dominate the MAHA Summit, and a look at Trump's watered down effort to lower Medicare drug prices.
- Country: United States
STAT+: A major insurer on how it may replicate Medicare’s chronic-care experiment
In this edition of STAT Health Tech: A California insurer on how it may replicate Medicare's tech-enabled chronic-care experiment.
- Country: United States
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
A final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposal